Clinical Cancer Drugs
Title:Preface
Volume: 5
Author(s): Giulio Francia
Affiliation:
Export Options
About this article
Cite this article as:
Francia Giulio , Preface, Clinical Cancer Drugs 2018; 5 (1) . https://dx.doi.org/10.2174/2212697X0501181101114141
DOI https://dx.doi.org/10.2174/2212697X0501181101114141 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |
20
2
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gonioprobe, an Innovative Gamma-probe to Guide Parathyroid Radioguided Surgery: First Clinical Experiences with Navigator and Lock-ontarget Functions
Current Radiopharmaceuticals Safety of Multi-Targeted Kinase Inhibitors as Monotherapy Treatment of Cancer: A Systematic Review of the Literature
Current Drug Safety Medical Applications of Collagen and Collagen-Based Materials
Current Medicinal Chemistry Evaluation on Auto-segmentation of the Clinical Target Volume (CTV) for Graves' Ophthalmopathy (GO) with a Fully Convolutional Network (FCN) on CT Images
Current Medical Imaging Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Targeting the STAT Pathway in Head and Neck Cancer: Recent Advances and Future Prospects
Current Cancer Drug Targets The Complexity of DEK Signaling in Cancer Progression
Current Cancer Drug Targets New Targets, New Agents, and the Evolving Phenomena of Drug Resistance in Cancer
Current Cancer Therapy Reviews Recent Patents in Oncolytic Virotherapy
Recent Patents on Biotechnology Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Subcellular Imaging and Diagnosis of Cancer using Engineered Nanoparticles
Current Pharmaceutical Design Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Biomedical Applications of Accelerator Mass Spectrometry
Current Analytical Chemistry B Cell Depletion in Systemic Vasculitis
Current Immunology Reviews (Discontinued) Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Important Anti-Cancer Applications of Protein Based Nanoparticles
Current Proteomics